APLS
USDApellis Pharmaceuticals Inc. Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$20.400
High
$20.610
Low
$19.440
Volume
5.10M
Company Fundamentals
Market Cap
2.5B
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
2.51M
Exchange
NMS
Currency
USD
52-Week Range
Related News
Mizuho Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $19
Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals with a Neutral and lowers the price target from $24 to $19.
Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $52 to $45.
TD Cowen Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
TD Cowen analyst Phil Nadeau maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $50 to $45.
Baird Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $52
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals with a Outperform and raises the price target from $50 to $52.
HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $57 to $45.
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in C3G and primary
Wells Fargo Upgrades Apellis Pharmaceuticals to Overweight, Raises Price Target to $32
Wells Fargo analyst Derek Archila upgrades Apellis Pharmaceuticals from Equal-Weight to Overweight and raises the price target from $29 to $32.
Related Stocks
GBR
New Concept Energy Inc
DUOL
Duolingo Inc.
PCTTU
PureCycle Technologies Inc. Unit
BOE
Blackrock Enhanced Global Dividend Trust Common Shares of Beneficial Interest
CGABL
The Carlyle Group Inc. 4.625% Subordinated Notes due 2061
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.